RELATED: Neurocrine exits $165M Parkinson's pact with Voyager after FDA holdĮfforts to develop gene and cell therapies for Parkinson's are underway, with mixed results so far. Bayer has started two early-stage trials: a gene therapy being developed by its subsidiary AskBio and a stem cell treatment from its unit BlueRock Therapeutics.
The insights could be used to develop tests that identify Parkinson's in people five to 10 years before it manifests, Surmeier suggested.
Now that this issue is resolved, we can focus our attention on developing therapies to preserve their function and slow the loss of these neurons," said James Surmeier, Ph.D., chair of neuroscience at Northwestern's Feinberg School of Medicine, in a statement. "Whether mitochondrial damage was a cause or consequence of the disease has long been debated.
0 kommentar(er)
